Edition:
United Kingdom

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

771.05INR
8:23am GMT
Change (% chg)

Rs-3.65 (-0.47%)
Prev Close
Rs774.70
Open
Rs779.80
Day's High
Rs783.10
Day's Low
Rs765.95
Volume
1,427,841
Avg. Vol
3,624,198
52-wk High
Rs827.45
52-wk Low
Rs527.00

Select another date:

Mon, Nov 12 2018

India's Aurobindo Pharma Q2 profit falls nearly 22 pct

Nov 12 Aurobindo Pharma Ltd, India's second-largest drugmaker by market capitalisation, posted a 21.7 percent fall in its second-quarter profit on Monday, hurt by higher expenses, but beat analysts' estimates.

Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

ZURICH/BENGALURU New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to $1 billion.

Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

ZURICH/BENGALURU New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to $1 billion.

UPDATE 3-Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

* Deal to result in $70 mln impairment for Novartis (Adds related content, detail about impairment in third graf, updates shares)

Novartis sells parts of Sandoz US to India's Aurobindo for $900 mln

Sept 6 Novartis AG said on Thursday it would sell the dermatology and generic U.S. oral solids portfolios of Sandoz U.S. to India's Aurobindo Pharma Ltd for $900 million, as the Swiss drugmaker looks to focus on higher growth areas.

BRIEF-Novartis Says To Divest Sandoz U.S. Dermatology Business And Generic U.S. Oral Solids Portfolio To Aurobindo

* NOVARTIS TO DIVEST SANDOZ US DERMATOLOGY BUSINESS AND GENERIC US ORAL SOLIDS PORTFOLIO TO AUROBINDO

BRIEF-Aurobindo Pharma Unit To Buy Commercial Ops And 3 Manufacturing Facilities From Sandoz

* UNIT AUROBINDO PHARMA USA ENTERED DEAL TO BUY COMMERCIAL OPERATIONS AND THREE MANUFACTURING FACILITIES IN USA FROM SANDOZ ., USA

India's Aurobindo Pharma Q1 profit misses estimates

Aug 9 Aurobindo Pharma Ltd reported a 12 percent fall in quarterly profit on Thursday and missed analysts' expectations, hurt by higher expenses.

India's Aurobindo Pharma Q4 profit misses estimates

May 28 India's Aurobindo Pharma Ltd posted a 0.6 percent fall in fourth-quarter net profit on Monday that missed analysts' estimates.

Select another date: